Shares of Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) have received a consensus rating of “Buy” from the seven analysts that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $6.60.
Several equities analysts have commented on ETTX shares. BMO Capital Markets dropped their price target on shares of Entasis Therapeutics from $15.00 to $5.00 and set an “outperform” rating for the company in a research note on Friday, May 8th. Wedbush restated an “outperform” rating and issued a $7.00 price target on shares of Entasis Therapeutics in a research note on Sunday, June 21st. CSFB restated an “outperform” rating and issued a $8.00 price target on shares of Entasis Therapeutics in a research note on Sunday, June 21st. Zacks Investment Research downgraded shares of Entasis Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, June 16th. Finally, Credit Suisse Group restated an “outperform” rating and issued a $8.00 price target on shares of Entasis Therapeutics in a research note on Sunday, June 21st.
In other news, major shareholder Innoviva, Inc. bought 12,677,490 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was purchased at an average price of $2.50 per share, for a total transaction of $31,693,725.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 15.40% of the company’s stock.
NASDAQ ETTX traded up $0.07 on Friday, reaching $2.94. The stock had a trading volume of 74,956 shares, compared to its average volume of 143,396. The firm has a market capitalization of $41.94 million, a price-to-earnings ratio of -0.84 and a beta of 2.09. The company has a quick ratio of 5.67, a current ratio of 5.67 and a debt-to-equity ratio of 0.04. Entasis Therapeutics has a 12-month low of $1.75 and a 12-month high of $9.25. The stock has a fifty day moving average price of $2.74 and a two-hundred day moving average price of $3.83.
Entasis Therapeutics (NASDAQ:ETTX) last announced its earnings results on Thursday, May 7th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.15). Sell-side analysts forecast that Entasis Therapeutics will post -2.27 earnings per share for the current fiscal year.
Entasis Therapeutics Company Profile
Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.
Recommended Story: Catch-Up Contributions
Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.